Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

HOERSHOLM, Denmark and SAN DIEGO, April 26 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

High cholesterol is a major risk factor for coronary heart disease, heart attack and stroke. According to the World Health Organization, high cholesterol is estimated to cause 18% of strokes and 56% of heart disease, globally and amounts to approximately 4.4 million deaths and 40.4 million disability-adjusted life years(1).

Santaris Pharma A/S presented preclinical data on SPC5001 last month at the PCSK9 Conference "From gene to therapeutics" in Nantes, France where many top pharmaceutical companies gathered to discuss efforts to develop therapies aimed at inhibiting the important new target PCSK9, a protein involved in regulating LDL (low-density lipoprotein) or "bad" cholesterol in the blood.

Data presented by Santaris Pharma A/S scientists showed that SPC5001 provided potent, specific and long-lasting inhibition of PCSK9 and lowered mean LDL cholesterol by 50% in non-human primates with a sustained reduction of 74% in the highest responder. SPC5001 did not change HDL (high-density lipoprotein) levels or the "good" cholesterol in the blood(2). The preclinical data suggest that SPC5001 has the potential to provide patients with a new treatment opti
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... today announced that it will release its unaudited financial ... after market close on Wednesday, August 12, 2015. The Company ... 2015, at 8:00 a.m. EDT (Thursday, August 13, 2015 ... Company,s financial results and provide an update on recent ...
(Date:8/3/2015)... 2015  ArroGen Group, an integrated advanced forensic ... Identification™ (FMID) technology Aug. 2-8 at the International ... Sacramento, Calif. FMID, a ... enforcement agents, district attorneys and government agencies to ... By analyzing chemical residues on fingerprints taken ...
(Date:8/3/2015)... , Aug. 3, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental ... at the 35 th Annual Canaccord|Genuity Growth Conference ... "Pete" Petit, Chairman and CEO, William C. Taylor ...
(Date:8/3/2015)... 2015  Merck KGaA, Darmstadt, Germany ... products in the healthcare, life science and performance materials ... their development and launch of promising new fullerene derivatives ... KGaA, Darmstadt, Germany , is pursuing ... Novel derivatives: highly stable, easy to process ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2ArroGen Previews New Fingerprint Molecular Identification Technology 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4
... April 13, 2012  The Large Urology Group Practice ... disputed a study published this week in the ... that the study grossly misrepresents the prevailing urological ... adopting evidence based clinical protocols. They pointed out ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global ... April 26, 2012. Results press release will be ... 14:00 BST / 09:00 EDT, , Live ... and Graham Hetherington, Chief Financial Officer will host the investor and ...
... increases the likelihood that it will be possible to predict ... without having to measure every aspect of it. That in ... silicothe goal of the proposed Human Brain Projecta more realistic, ... a world of predictive biology," says Henry Markram, the senior ...
Cached Biology Technology:Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study 2Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study 3Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study 4Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012 2Data mining opens the door to predictive neuroscience 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... certified winner of the UC Davis "Western Cooling Challenge" ... that their five-ton commercial rooftop unit should be able ... half the energy needed by conventional cooling units. ... first to take our rigorous tests at the Advanced ...
... Leipzig Max Planck Institute for Human Cognitive and Brain ... London have now developed a mathematical model which could ... language. In the future, this kind of algorithms which ... world around them. Many people will have personal ...
... cells for replication and production of virus progeny. Thus ... induces therapy resistance. New improved therapies attempt to targets ... The team led by Professor Dr. Ralf Bartenschlager, ... Hygiene Institute of Heidelberg University Hospital, has identified a ...
Cached Biology News:UC Davis challenge produces a better air conditioner 2Doing what the brain does -- how computers learn to listen 2Doing what the brain does -- how computers learn to listen 3New strategy for inhibiting virus replication 2
... NTI Suite for Mac OS X provides ... DNA and protein sequence analysis and molecular ... X. With Vector NTI Suite you can ... publicize diverse types of molecular biology data ...
... applications. Multiple solvents can be used, such as water, benzene, formamide, nitrobenzene, cyclohexane, 1,4-dioxane, p-xylene, ... * Range: 12-position ... ... ...
rat Leptin...
SHEEP ANTI ESCHERICHIA COLI...
Biology Products: